Acumen Pharmaceuticals (ABOS)
(Delayed Data from NSDQ)
$3.49 USD
+0.01 (0.29%)
Updated May 3, 2024 04:00 PM ET
After-Market: $3.50 +0.01 (0.29%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum D VGM
Brokerage Reports
Acumen Pharmaceuticals, Inc. [ABOS]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ALTITUDE-AD Designed to Assess Risk Benefit Profile of SabirnetugOur Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Live from AD/PD 2024 Lisbon-Mechanistic Insights on ARIA Exploring the Role of Classical Complement Pathway Activation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging CSF Biomarker Data Supportive of ACU193s MOA
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from CTAD 2023¯Implications for the Next Generation Anti-AmyloidsThis report contains brief updates on the following: ABOS, ACIU, ALEC, BIIB, DNLI, PRTA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INTERCEPT-AD Top Line Data Pave Way for the Phase 2/3 ProgramKey Takeaways
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Robust Target Engagement and Safety Data Might Take ACU193 to Phase 2/3; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Setting Expectations for INTERCEPT-AD; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on Protocol Amendment for INTERCEPT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways for Acumen From the Current Anti Abeta Trial Readouts; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Beginning of an Era of Anti-Amyloids and Combination Therapies in Alzheimer''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Pubmed Times¯Focusing on the Need to Pull Down Toxic Oligomers
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Learnings from the Recent Anti-Abeta Trials Supportive of ACU193s MOA; Reiterate Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on API ADAD Data Readout-Implications for Anti-Abeta Therapy Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acumen Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Acumen Ditches Plaque for Safety and Efficacy - Initiating With a Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
|